Piper Sandler analyst Christopher Raymond downgraded Deciphera to Neutral from Overweight with a price target of $25.60, up from $23, after the company entered a definitive merger agreement under which ONO Pharmaceutical will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds